{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:13:06Z","timestamp":1788833586603,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T00:00:00Z","timestamp":1545004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.jbo.2018.100212","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T03:11:38Z","timestamp":1545102698000},"page":"100212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9165-1444","authenticated-orcid":false,"given":"Jean-Jacques","family":"Body","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"von Moos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Rider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Hallworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debajyoti","family":"Bhowmik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Hechmati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbo.2018.100212_bib0001","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2018.100212_bib0002","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1053\/hp.2000.6698","article-title":"Metastatic patterns of prostate cancer: an autopsy study of 1589 patients","volume":"31","author":"Bubendorf","year":"2000","journal-title":"Hum. Pathol."},{"issue":"Suppl 3","key":"10.1016\/j.jbo.2018.100212_bib0003","doi-asserted-by":"crossref","first-page":"iii124","DOI":"10.1093\/annonc\/mdu103","article-title":"Bone health in cancer patients: ESMO clinical practice guidelines","volume":"25","author":"Coleman","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jbo.2018.100212_bib0004","first-page":"237","article-title":"Burden of skeletal-related events in prostate cancer: unmet need in pain improvement","volume":"23","author":"Broder","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jbo.2018.100212_bib0005","first-page":"869","article-title":"Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer","volume":"15","author":"DePuy","year":"2007","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jbo.2018.100212_bib0006","first-page":"1327","article-title":"Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases","volume":"24","author":"von Moos","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jbo.2018.100212_bib0007","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jbo.2018.100212_bib0008","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3816\/SCT.2005.n.017","article-title":"Survival-adjusted multiple-event analysis for the evaluation of treatment effects of zoledronic acid in patients with bone metastases from solid tumors","volume":"2","author":"Major","year":"2005","journal-title":"Support Cancer Ther."},{"key":"10.1016\/j.jbo.2018.100212_bib0009","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10198-015-0716-7","article-title":"Health resource utilization associated with skeletal-related events: results from a retrospective European study","volume":"17","author":"Body","year":"2016","journal-title":"Eur. J. Health Econ."},{"key":"10.1016\/j.jbo.2018.100212_bib0010","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3111\/13696998.2013.779921","article-title":"Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study","volume":"16","author":"Hechmati","year":"2013","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.jbo.2018.100212_bib0011","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jbo.2014.04.001","article-title":"Health resource utilization associated with skeletal-related events in patients with bone metastases: results from a multinational retrospective \u2013 prospective observational study \u2013 a cohort from 4 European countries","volume":"3","author":"Hoefeler","year":"2014","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.jbo.2018.100212_bib0012","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3111\/13696998.2016.1150852","article-title":"Cost of skeletal complications from bone metastases in six European countries","volume":"19","author":"Pereira","year":"2016","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.jbo.2018.100212_bib0013","first-page":"335","article-title":"Prevalence of bone metastases and bone-targeting agent use among solid tumor patients in the United States","volume":"7","author":"Hernandez","year":"2015","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.jbo.2018.100212_bib0014","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jbo.2018.100212_bib0015","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jbo.2018.100212_bib0016","first-page":"3497","article-title":"Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid","volume":"21","author":"von Moos","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jbo.2018.100212_bib0017","unstructured":"Zometa (zoledronic acid): summary of product characteristics https:\/\/www.ema.europa.eu\/documents\/product-information\/zometa-epar-product-information_en.pdf Accessed 14 November 2018."},{"key":"10.1016\/j.jbo.2018.100212_bib0018","unstructured":"Xgeva (denosumab): summary of product characteristics https:\/\/www.ema.europa.eu\/documents\/product-information\/xgeva-epar-product-information_en.pdf Accessed 14 November 2018."},{"key":"10.1016\/j.jbo.2018.100212_bib0019","unstructured":"ZYTIGA (abiraterone acetate): summary of product characterisitcs https:\/\/www.ema.europa.eu\/documents\/product-information\/zytiga-epar-product-information_sv.pdf Accessed 14 November 2018."},{"key":"10.1016\/j.jbo.2018.100212_bib0020","unstructured":"Xtandi (enzalutamide): summary of product characteristics https:\/\/www.ema.europa.eu\/documents\/product-information\/xtandi-epar-product-information_en.pdf Accessed 14 November 2018."},{"key":"10.1016\/j.jbo.2018.100212_bib0021","unstructured":"Xofigo (radium-223): summary of product characteristics https:\/\/www.ema.europa.eu\/documents\/product-information\/xofigo-epar-product-information_en.pdf Accessed 11 November 2018."},{"key":"10.1016\/j.jbo.2018.100212_bib0022","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/S1470-2045(12)70473-4","volume":"13","author":"Logothetis","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jbo.2018.100212_bib0023","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(14)70303-1","article-title":"Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial","volume":"15","author":"Fizazi","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jbo.2018.100212_bib0024","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","article-title":"Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial","volume":"15","author":"Sartor","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jbo.2018.100212_bib0025","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1185\/03007990802457040","article-title":"Real-world physician and patient behaviour across countries: disease-specific programmes \u2013 a means to understand","volume":"24","author":"Anderson","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jbo.2018.100212_bib0026","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010352","article-title":"Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the disease specific programme","volume":"6","author":"Babineaux","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.jbo.2018.100212_bib0027","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/DMSO.S120101","article-title":"Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015","volume":"9","author":"Higgins","year":"2016","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"10.1016\/j.jbo.2018.100212_bib0028","unstructured":"The brief pain inventory user guide https:\/\/www.mdanderson.org\/documents\/Departments-and-Divisions\/Symptom-Research\/BPI_UserGuide.pdf Accessed 14 November 2018."},{"key":"10.1016\/j.jbo.2018.100212_bib0029","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/pme.12299","article-title":"Assessing analgesic use in patients with advanced cancer: development of a new scale \u2013 the analgesic quantification algorithm","volume":"15","author":"Chung","year":"2014","journal-title":"Pain Med."},{"key":"10.1016\/j.jbo.2018.100212_bib0030","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol \u2013 a new facility for the measurement of health-related quality of life","volume":"16","year":"1990","journal-title":"Health Policy"},{"key":"10.1016\/j.jbo.2018.100212_bib0031","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/S0090-4295(97)00459-7","article-title":"Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument","volume":"50","author":"Esper","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.jbo.2018.100212_bib0032","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1185\/03007995.2010.535511","article-title":"Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis","volume":"27","author":"Hatoum","year":"2011","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jbo.2018.100212_bib0033","first-page":"e12490","article-title":"The use of bisphosphonates in the management of bone metastases from solid tumours and haematological malignancies \u2013 a European survey","volume":"26","author":"Lebret","year":"2016","journal-title":"Eur. J. Cancer Care"},{"key":"10.1016\/j.jbo.2018.100212_bib0034","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.urology.2012.04.007","article-title":"Treatment patterns in patients with prostate cancer and bone metastasis among US community-based urology group practices","volume":"80","author":"Freedland","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.jbo.2018.100212_bib0035","doi-asserted-by":"crossref","first-page":"465","DOI":"10.5489\/cuaj.117","article-title":"Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: incorporating new agents into clinical practice","volume":"6","author":"So","year":"2012","journal-title":"Can. Urol. Assoc. J."},{"key":"10.1016\/j.jbo.2018.100212_bib0036","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.eururo.2015.04.032","article-title":"Impact of bone-targeted therapies in chemotherapy-na\u00efve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302","volume":"68","author":"Saad","year":"2015","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jbo.2018.100212_bib0037","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.5034","article-title":"Radium-223 in an international early access program (EAP): effects of concomitant medication on overall survival in metastatic castration-resistant prostate cancer (mCRCP) patients","volume":"33","author":"Saad","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2018.100212_bib0038","unstructured":"M. Smith, P. Parker, M. Saad, K. Miller, B. Tombal, Q.S. Ng, et al., Abiraterone acetate and prednisone\/prednisolone in combination with radium-223 or placebo in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3 trial, [Abstract LBA30] Presented at the Annual Meeting of the European Society of Medical Oncology, 19\u201323 October 2018, Munich, Germany."},{"key":"10.1016\/j.jbo.2018.100212_bib0039","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10147-012-0414-8","article-title":"Treatment of bone metastases before the onset of pain","volume":"18","author":"Costa","year":"2013","journal-title":"Int. J. Clin. Oncol."},{"issue":"Suppl 7","key":"10.1016\/j.jbo.2018.100212_bib0040","doi-asserted-by":"crossref","first-page":"vii139","DOI":"10.1093\/annonc\/mds233","article-title":"Management of cancer pain: ESMO clinical practice guidelines","volume":"23","author":"Ripamonti","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2018.100212_bib0041","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1038\/sj.bjc.6605053","article-title":"Pattern and quality of care of cancer pain management. Results from the cancer pain outcome research study group","volume":"100","author":"Apolone","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jbo.2018.100212_bib0042","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/annonc\/mdn419","article-title":"Prevalence of undertreatment in cancer pain. A review of published literature","volume":"19","author":"Deandrea","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2018.100212_bib0043","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1200\/JCO.2011.39.2381","article-title":"Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer","volume":"30","author":"Fisch","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2018.100212_bib0044","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1056\/NEJM199403033300902","article-title":"Pain and its treatment in outpatients with metastatic cancer","volume":"330","author":"Cleeland","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2018.100212_bib0045","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S1470-2045(12)70040-2","article-title":"Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC","volume":"13","author":"Caraceni","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jbo.2018.100212_bib0046","unstructured":"NCCN clinical practice guidelines in oncology. Adult cancer pain version https:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/pain.pdf Accessed 14 November 2018."},{"key":"10.1016\/j.jbo.2018.100212_bib0047","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137418301155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137418301155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:16:58Z","timestamp":1761941818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137418301155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":47,"alternative-id":["S2212137418301155"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2018.100212","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2018.100212","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100212"}}